Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
  • Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study
  • Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced yet familiar experience for patients
  • Submission builds on Sandoz’ well established biosimilar immunology portfolio in Europe

Basel, June 17, 2022 — Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration  …

/by
HEXAL launches Dimethyl fumarate HEXAL® a generic drug for Tecfidera®, in Germany, offering an economically efficient treatment option for the care of adult patients with multiple sclerosis*
  • Dimethyl fumarate HEXAL® is bioequivalent to the originator product 1,2,3
  • Additional 196 pack size reduces co-payment burden for patients

Basel, June 10, 2022 — Sandoz expands its portfolio and today announces the launch of the generic drug Dimethyl fumarate HEXAL®, which  is approved for the treatment of adults with relapsing remitting  multiple sclerosis  (RRMS) 1, in Germany.

“We are proud to introduce a generic drug for German patients for the treatment of …

/by